Sarosdy M F
Division of Urology, University of Texas Health Science Center, San Antonio 78284-7845, USA.
Eur Urol. 1997;31 Suppl 1:5-9. doi: 10.1159/000474525.
Bropirimine is an oral immunostimulant found to have efficacy in human transitional cell carcinoma in situ following the initial discovery of its antitumor activity against the murine bladder cancer MBT-2. To determine if bropirimine might have activity in prostate cancer, it was tested against two rodent prostate cancer cell lines in vivo.
Tumors resulted from subcutaneous injection of PAIII and Dunning MAT-LyLu rodent prostate cancer cells. Bropirimine was given at 250 mg/kg orally on different schedules, and tumor volume and survival were recorded.
In the PAIII model, bropirimine prevented growth when given the day of tumor injection, and 95% of advanced tumors regressed completely when start of therapy was delayed. Bropirimine also caused growth inhibition and prolongation of survival in the MAT-LyLu model.
Bropirimine immunotherapy is very effective in vivo against the PAIII cell line, and it has significant growth inhibition against the Dunning MAT-LyLu cell line.
布罗匹明是一种口服免疫刺激剂，在最初发现其对鼠膀胱癌MBT - 2具有抗肿瘤活性后，发现它对人原位移行细胞癌有效。为了确定布罗匹明是否对前列腺癌有活性，在体内对两种啮齿类前列腺癌细胞系进行了测试。
通过皮下注射PAIII和邓宁MAT - LyLu啮齿类前列腺癌细胞形成肿瘤。布罗匹明以250mg/kg的剂量按不同给药方案口服，并记录肿瘤体积和生存期。
在PAIII模型中，肿瘤注射当天给予布罗匹明可阻止肿瘤生长，当治疗开始延迟时，95%的晚期肿瘤完全消退。布罗匹明在MAT - LyLu模型中也引起生长抑制并延长生存期。
布罗匹明免疫疗法在体内对PAIII细胞系非常有效，并且对邓宁MAT - LyLu细胞系有显著的生长抑制作用。
